ArticleOncoimmunology2020
Co-localization of CD169
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- The Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients With Breast Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies.Frontiers in immunology · 2026Review
- Placenta-derived trophoblast extracellular vesicles promote CD169Journal of translational medicine · 2025Article
- Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages.Molecular cancer · 2025Article
- Altered immune signatures in breast cancer lymph nodes with metastases revealed by spatial proteome analyses.Journal of translational medicine · 2025Article
- Exploring CD169Vaccines · 2025Review
- Evaluation of programmed cell death ligand-1 expression in primary central nervous system lymphoma using whole-tumor histogram analysis of multiparametric MRI: implications for immunotherapy selection.Frontiers in immunology · 2025Article
- Association between programmed cell death ligand-1 expression in patients with cervical cancer and apparent diffusion coefficient values: a promising tool for patient´s immunotherapy selection.European radiology · 2024Article
- Anticancer immune reaction and lymph node sinus macrophages: a review from human and animal studies.Journal of clinical and experimental hematopathology : JCEH · 2024Review
- Understanding tissue-resident macrophages unlocks the potential for novel combinatorial strategies in breast cancer.Frontiers in immunology · 2024Review
- Mechanisms and characteristics of subcapsular sinus macrophages in tumor immunity: a narrative review.Translational cancer research · 2023Review
- CD169Cancers · 2023Article
- Breast cancer associated CD169Frontiers in immunology · 2023Article
- CD169Research and reports in urology · 2023Article
- High Expression of RAI14 in Triple-Negative Breast Cancer Participates in Immune Recruitment and Implies Poor Prognosis Through Bioinformatics Analyses.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common form of cancer in women worldwide. Although the survival among breast cancer patients has improved, there is still a large group of patients with dismal prognosis. One of the most important prognostic factors for poor prognosis is lymph node metastasis. Increasing knowledge concerning the lymph nodes of breast cancer patients indicates that they are affected by the primary tumor. In this study we show that presence of CD169
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.